Search Results - elizabeth inks

1 Results Sort By:
Novel class I HDAC inhibitors that are impervious to glucuronidation for the treatment of hematologic malignancies and inflammatory diseases/disorders
MUSC researchers have developed a series of potent and selective class I histone deacetylase (HDAC) inhibitors. Currently, approved HDAC inhibitors are generated using hydroxamic acid or a benzylic amine motif and suffer from toxicity, off-target effects, and metabolic inactivation. Furthermore, the first generation HDAC inhibitors have been shown...
Published: 2/1/2017   |   Inventor(s): Chung-Jen (James) Chou, Jesse Mcclure, Cheng Zhang, Elizabeth Inks
Keywords(s):  
Category(s): Therapeutic
© 2018. All Rights Reserved. Powered by Inteum